Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

LBH 2022 > MABs > Flashcards

MABs Flashcards

1
Q

Adalimumab

A

Anti-TNF

Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Afatinib

A

TK inhibitor - EGFR, ERBB2, ERBB4

NSCLC (EGFR mutation +ve excluding T790M)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alemtuzumab

A

Anti-CD52 (Humanised IgG1)

CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anakinra

A

IL1 blockade

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Axitinib

A

TK inhibitor - VEGFR1/2/3, PDGFRb, c-KIT

RCC (2nd line)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Basiliximab

A

Anti-IL2R

Transplant
Anti-CD25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Belatacept

A

T cell co-stimulation blocker (Fc protein + CTLA4)

Transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Belimumab

A

Anti-BLYs/BAFF
Inhibits B cell proliferation/survival

SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benralizumab

A

Anti-IL5 R alpha

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bevacizumab

A

Bevacizumab is a recombinant, humanized monoclonal antibody.
Neturalizes VEGF, preventing its association with endothelial receptors, Flt-1 and KDR

CRC
Ovarian cancer
CNS cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bezlotoxumab

A

Anti-C.diff toxin B

C.diff recurrent infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Blinatumomab

A

Bi-specific T-cell engaging antibody

Acute lymphoblastic leukaemia (relapsed disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bortezomib

A

Proteasome inhibitor
-Inhibit NF-kappa B

Multiple myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brentuximab

A

Anti-CD30 conjugated antibody

Hodgkin’s Disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Brodalumab

A

Anti-17R

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Canakinumab

A

Anti-IL1b

Rheumatoid arthritis
Autoinflammatory disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Certolizumab pegol

A

Anti-TNF

Crohn’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cetuximab

A

EGFR inhibitor

Head and neck SCC
Metastatic CRC

Must be KRAS Wild Type!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Criznlizumab

A

P-selectin glycoprotein ligand 1

Sickle cell crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Crizotinib

A

TK inhibitor - ALK and Ros1 inhibitor

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dabrafenib

A

TK inhibitor - BRAF

Melanoma (BRAF V600)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Daclizumab

A

Anti-IL2R

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Dasatinib

A

TK inhibitor

Bcr-Abl, SRC, c-kit, ephrin receptors

CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Denosumab

A

Denosumab binds to RANKL, blocks the interaction between RANKL and RANK (a receptor located on osteoclast surfaces), and prevents osteoclast formation, leading to decreased bone resorption and increased bone mass in osteoporosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Eculizumab
Anti-C5 PNH aHUS
26
Efalizumab
Anti-CD11a Psoriasis
27
Eltrombopag
Eltrombopag is a thrombopoietin (TPO) nonpeptide agonist which increases platelet counts by binding to and activating the human TPO receptor. Activates intracellular signal transduction pathways to increase proliferation and differentiation of marrow progenitor cells. ITP
28
Erlotinib
TK inhibitor - EGFR receptor NSCLC (EGFR Mutation +ve, excluding T790M)
29
Evolocumab
PCSK9 inhibitor Familial hypercholesterolaemia
30
Etanercept
TNF blockade RA PsA Ank Spon
31
Gefitinib
TK inhibitor - EGFR NSCLC (EGFR mutation +ve, excluding T790M)
32
Golimumab
Anti-TNF RA PsA Ank Spon
33
Ibritumomab tiuxetan
Anti-CD20 NHL
34
Ibrutinib
BTK inhibitor (B cells) ``` CLL Waldenstrom's Mantle cell lymphoma Marginal zone lymphoma Chronic GVHD ```
35
Idarucizumab
Dabigatran reversal
36
Imatinib
TK Inhibitor - BCR-ABL pathway CML (Ph+) GIST ALL (Ph+)
37
Infliximab
Anti-TNF Crohn's disease
38
Ipilimumab
Anti-CTLA4 Metastatic melanoma
39
Ixekizumab
Anti-IL17a Psoriasis
40
Lapatinib
TK inhibitor - HER2 HER2+ Breast cancer (2nd line)
41
Mepolizumab
Anti-IL5 Asthma
42
Mongersen
SMAD7 Antisense olignucleotide Crohn's
43
Nataolizumab
Anti-a4 integrin Multiple sclerosis
44
Nilotinib
TK Inhibitor - Bcr-Abl kinase CML GIST - off label
45
Nintedanib
TKI - BEGFR, FGFR Idiopathic pulmonary fibrosis
46
Nivolumab
Anti-PD1 Melanoma
47
Obinutuzumab Anti-CD20 CLL
48
Ofatumumab Anti-CD20 CLL
49
Omalizumab
Anti-IgE Asthma
50
Olaparib
TK inhibitor - PARP BRCA mutated high-grade serious epithelial ovarian ca Fallopian tube Primary peritoneal ca
51
Osimmertinib
EGFR TKI NSCLC T790M mutation EGFR gene
52
Palibociclib
CDK4/6 inhibitor ER+ Breast Ca
53
Panitumumab
Anti-EGFR CRC
54
Pazopanib
BEGFR1/2/3, PDGFR, KIT RCC Sarcoma
55
Pembrolizumab
Anti-PD1 Melanoma Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding.
56
Peruzumab
Anti-HER2/HER3 Extracellular dimerization domain of HER2
57
Ponatinib
BCR-ABL1 TKI
58
Quizartinib
FLT-3 inhibitor
59
Ramucirumab
Anti-VEGF receptor | Gastric ca
60
Reslizumab
Anti-CD20 NHL
61
Romosozumab
Sclerostin inhibitor Osteoporosis
62
Ruxolitinib
Jak1/2/ inhibitor Myeloproliferation
63
Secukinumab
Anti-IL17a Psoriasis
64
Siltuximab
Anti-IL 6 Castleman disease
65
Sorafenib
TK inhibitor - BEGFR2/3, PDGFR, C-Raf> B-raf, KIT Advanced RCC Unresectable HCC Thyroid ca
66
Sunitinib
TK inhibitor - FGF, PDGFR, RET, FLT3, VEGFR1/2 receptors, CD 117 (c-KIT) inhibitor GIST RCC Pancreatic neuroendocrine tumours
67
Tocilizumab
Anti-IL6R (Humanised IgG1) RA GCA
68
Tofacitinib
Jak3 inhibitor RA
69
Tositumomab
Anti-CD20 NHL
70
Trastuzumab
Anti-HER2 (extracellular) Metastatic breast ca (HER2+) GI cancer
71
Ustekinumab
Anti-IL12/23 Psoriasis
72
Vedolizumab
Anti-a4b7 integrin UC CD
73
Vemurafenib
TK inhibitor - B-Raf inhibitor Melanoma (BRAF V600 mutation)
74
Dupilumab
Anti- IL4, IL 13 Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent Atopic dermatitis Rhinosinusitis (chronic) with nasal polyposis

LBH 2022 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions